Molecular biomedicine and the unraveling of complex phenotypes

Journal of Applied Genetics

Volumn 45, Issue 4, 2004, Pages 395-397

  Pignatti, Pier Franco ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; SALBUTAMOL;

ASTHMA; BIOMEDICINE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL PRACTICE; DRUG METABOLISM; DRUG TARGETING; EDITORIAL; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEALTH CARE; HEALTH EDUCATION; HEREDITY; LIFESTYLE; LIPID METABOLISM; MOLECULAR BIOLOGY; MUTATION; PHARMACOGENOMICS; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 10444234391     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (30)

1. A polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 15: 89-93.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, et al. 2004b. 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 15: 427-433.
3. Botstein D, Risch N, 2003. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet suppl 33: 228-237.
4. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al. 2002. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 156: 311-318.
5. Cheng S, Pallaud C, Grow MA, Klitz W, Erlich HA, Visvikis S, et al. 1998. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med 36: 561-566.
6. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, et al. 1999. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9: 936-949.
7. Collins FS, Green ED, Guttmacher AE, Guyer MS, 2003. A vision for the future of genomics research. Nature 422: 835-847.
8. Collins FS 2004. The case for a US prospective cohort study of genes and environment. Nature 429: 475-477.
9. Dekker MC, Duijn CM, 2003. Prospects of genetic epidemiology in the 21st century. Eur J Epidemiol 18: 607-616.
10. Evans WE, McLeod HL, 2003. Pharmacogenomics - drug disposition, drug targets, and side effects. New Engl J Med 348: 538-549.
11. Evans PDA, Relling MV, 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491.
12. Freimer N, Sabatti C, 2003. The human phenome project. Nat Genet 34: 15-21.
13. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. 1998. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 91: 4158-4163.
14. Girelli D, Martinelli N, Pizzolo F, Friso S, Olivieri O, Stranieri C, et al. 2003. The interaction between MTHFR 677 C->T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr 133: 1281-1285.
15. Ingelman-Sundberg M, 2001. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250: 186-200.
16. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH, 1999. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340: 1449-1454.
17. Jasny BR, Roberts L, 2003. Are we there yet? Science 302: 587.
18. 311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 34: 14-20.
19. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R, 1997. Association between genetic polymorphisms of the beta2-adrenoreceptor and response to Albuterol in children with and without a history of wheezing. J Clin Invest 100: 3184-3198.
20. Merikangas KR, Risch N, 2003. Genomic priorities and public health. Science 302: 599-601.
21. Peltonen L, McKusick VA, 2001. Genomics and medicine. Dissecting human disease in the postgenomic era. Science 291: 1224-1229.
22. Peyser PA, 1997. Genetic epidemiology of coronary artery disease. Epidemiological Reviews 19: 80-90.
23. Petricoin EF, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, et al. 2002. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet Suppl. 32: 479-479.
24. Pignatti PF, 2004. Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol Res 49: 343-349.
25. Quinzii C, Belpinati F, Pignatti PF, 2001. Predictive genetic testing - new possibilities in determination of risk of complex diseases. Croat Med J 42: 458-462.
26. Risch NJ, 2000. Searching for genetic determinants in the new millennium. Nature 405: 847-856.
27. Wald DS, Law M, Morris JK, 2002. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325: 1202-1208.
28. Weinshilbaum R, 2003. Inheritance and drug response. New Engl J Med 348: 529-537.
29. Weinshilbaum R, Wang 2004. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3: 739-748.
30. Wright A, Charlesworth B, Rudan I, Carothers A, Campbell H, 2003. Polygenic basis for late-onset disease. Trends Genet 19: 97-106.